Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03716726 · ClinicalTrials.gov registry record · NA

Sickle Cell Anemia WE CARE

A NA study of Sickle Cell Disease, sponsored by Boston Medical Center.

Completed
Registry status
NA
Development phase
112
Enrollment target
1
Study location

NCT03716726 is a NA study of Sickle Cell Disease that has completed, run by Boston Medical Center. The registered enrollment target is 112 participants, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (62% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03716726, a NA study of Sickle Cell Disease, has completed, sponsored by Boston Medical Center.

COMPLETED
Registry status
NA
Development phase
112 participants
Enrollment target
1
Study location

Study Summary

This mixed-methods study aims to understand the implementation of a previously tested, efficacious social determinants of health (SDoH) screening and referral intervention in the outpatient pediatric hematology setting; qualitatively assess possible mechanisms for such interventions on improving child health; and obtain population-specific empirical estimates to plan a large-scale clinical trial.

Conditions Studied

Interventions

  • OTHER Standard of care
  • BEHAVIORAL WE CARE SDoH Screening Survey
  • BEHAVIORAL Family Resource Book

Study Locations (1)

Massachusetts

  • Boston Medical Center - Boston

Trial Details

FieldValue
Enrollment Target 112 participants
Start Date 2021-01-21
Est. Completion 2023-02-01
Phase NA

Sponsor

Boston Medical Center

253 total trials

What the Registry Record Tells You About NCT03716726

The ClinicalTrials.gov registry entry for NCT03716726 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 112 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (62% lower). The listed sponsor is Boston Medical Center, which has 253 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Sickle Cell Disease appearing as the primary indexed condition, and to 3 interventions - of which Standard of care is the first listed.

NCT03716726 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT03716726 about?

NCT03716726 is a clinical study titled "Sickle Cell Anemia WE CARE". This mixed-methods study aims to understand the implementation of a previously tested, efficacious social determinants of health (SDoH) screening and referral intervention in the outpatient pediatric hematology setting; qualitatively assess possible mechanisms for such interventions on improving chi...

What is the current status of trial NCT03716726?

This trial is currently completed. It is a NA study. The enrollment target is 112 participants. The study started on 2021-01-21. Estimated completion is 2023-02-01.

What conditions does trial NCT03716726 study?

This clinical trial studies the following conditions: Sickle Cell Disease.

What interventions are being tested in trial NCT03716726?

The interventions under investigation include: Standard of care (OTHER), WE CARE SDoH Screening Survey (BEHAVIORAL), Family Resource Book (BEHAVIORAL).

Who is sponsoring clinical trial NCT03716726?

This trial is sponsored by Boston Medical Center, which has 253 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03716726 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Sickle Cell Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.